CIALIS Drug Patent Profile

Which patents cover Cialis, and when can generic versions of Cialis launch?

Cialis is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in CIALIS is tadalafil. There are twenty-five drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the tadalafil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cialis

A generic version of CIALIS was approved as tadalafil by TEVA PHARMS USA on May 22^nd, 2018.

Summary for CIALIS

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	91
Clinical Trials:	95
Patent Applications:	6,652
Drug Prices:	Drug price information for CIALIS
Drug Sales Revenues:	Drug sales revenues for CIALIS
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CIALIS
What excipients (inactive ingredients) are in CIALIS?	CIALIS excipients list
DailyMed Link:	CIALIS at DailyMed

See drug prices for CIALIS

See drug sales revenues for CIALIS

Recent Clinical Trials for CIALIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Arizona	Phase 2
University of Florida	Phase 2/Phase 3
Dongkook Pharmaceutical Co., Ltd.	Phase 3

See all CIALIS clinical trials

Pharmacology for CIALIS

Drug Class	Phosphodiesterase 5 Inhibitor
Mechanism of Action	Phosphodiesterase 5 Inhibitors

Paragraph IV (Patent) Challenges for CIALIS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CIALIS	Tablets	tadalafil	2.5 mg	021368	1	2008-10-14
CIALIS	Tablets	tadalafil	5 mg, 10 mg and 20 mg	021368	1	2007-11-21

US Patents and Regulatory Information for CIALIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008		DISCN	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003	AB1	RX	Yes	Yes
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003	AB1	RX	Yes	No
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003	AB1	RX	Yes	No

Expired US Patents for CIALIS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003	6,140,329
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-003	Nov 21, 2003	5,859,006*PED
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-001	Nov 21, 2003	7,182,958*PED
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008	5,859,006*PED
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-002	Nov 21, 2003	7,182,958*PED

EU/EMA Drug Approvals for CIALIS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Viatris Limited	Talmanco (previously Tadalafil Generics)	tadalafil	EMEA/H/C/004297Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.	Authorised	yes	no	no	2017-01-09
Eli Lilly Nederland B.V.	Tadalafil Lilly	tadalafil	EMEA/H/C/004666Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.	Authorised	no	no	no	2017-03-22
Eli Lilly Nederland B.V.	Adcirca (previously Tadalafil Lilly)	tadalafil	EMEA/H/C/001021AdultsTreatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see section 5.1).Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.Paediatric populationTreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III.	Authorised	no	no	no	2008-10-01
Eli Lilly Nederland B.V.	Cialis	tadalafil	EMEA/H/C/000436Treatment of erectile dysfunction.In order for tadalafil to be effective, sexual stimulation is required.Cialis is not indicated for use by women.	Authorised	no	no	no	2002-11-12
Mylan Pharmaceuticals Limited	Tadalafil Mylan	tadalafil	EMEA/H/C/003787Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Mylan is not indicated for use by women.	Authorised	yes	no	no	2014-11-21

International Patents for CIALIS

See the table below for patents covering CIALIS around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2226784	UTILISATION D'INHIBITEURS DE PHOSPHODIESTERASE SPECIFIQUE DE GMPC DANS LE TRAITEMENT DE L'IMPUISSANCE (USE OF CGMP-PHOSPHODIESTERASE INHIBITORS TO TREAT IMPOTENCE)
New Zealand	504163	A pharmaceutical collocation comprising a PDE5 inhibitor, a package and a label
Croatia	P950023	TETRACYCLIC DERIVATIVES, PROCESS OF PREPARATION AND USE
Norway	20020532
Slovenia	20361	Visoko selektivni fosfodiesterazni (PDE) encimski inhibitorji (HIGHLY SELECTIVE PHOSPHODIESTERASE (PDE) ENZYME INHIBITORS)

Supplementary Protection Certificates for CIALIS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2059246	C202430051	Spain		PRODUCT NAME: UNA COMBINACION DE (A) MACITENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO Y (B) TADALAFILO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/24/1859; DATE OF AUTHORISATION: 20240927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/24/1859; DATE OF FIRST AUTHORISATION IN EEA: 20240927
2059246	C02059246/01	Switzerland		PRODUCT NAME: MACITENTAN UND TADALAFIL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69446 10.10.2024
2101777	93081	Luxembourg		PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
2059246	301308	Netherlands		PRODUCT NAME: EEN COMBINATIE VAN (A) MACITENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN (B) TADALAFIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1859 20240930
2059246	2490043-3	Sweden		PRODUCT NAME: A COMBINATION OF (A) MACITENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) TADALAFIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/24/1859 20240930

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: CIALIS

Last updated: January 14, 2026

Executive Summary

CIALIS (tadalafil), marketed primarily by Eli Lilly and Co., is a leading oral treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). Over the past decade, the drug has maintained a robust market presence driven by high efficacy, favorable safety profile, and diversified indications. The global CIALIS market experienced significant growth, with estimated revenues reaching over $2 billion annually prior to the COVID-19 pandemic. Future trajectories are poised to benefit from expanding indications, increased global adoption, and evolving healthcare policies, although competitive pressures and patent expirations pose risks.

This comprehensive analysis examines market dynamics, revenue streams, competitive landscape, regulatory environment, and forecasted financial trajectories, equipping stakeholders with the insights needed to navigate CIALIS's evolving market.

---

Market Overview of CIALIS

Indications and Usage

Primary Indications	Description	Market Penetration
Erectile Dysfunction (ED)	Improves erectile function via PDE5 inhibition.	~80% of revenues
Benign Prostatic Hyperplasia (BPH)	Alleviates urinary symptoms associated with BPH.	~20% of revenues (growth segment)
Pulmonary Arterial Hypertension (PAH)	Approved for PAH in some regions, but minimal revenue contribution.	Negligible

Key Market Players

Company	Product	Market Share (Estimated)	Additional Notes
Eli Lilly	CIALIS	~60%	Dominant in ED/BPH segment
Others	Viagra (Pfizer), Stendra (Stendra), Levitra (Bayer)	Remaining share	Competition mainly from other PDE5 inhibitors

Geographic Market Breakdown

Region	Market Share	Key Trends	Notes
North America	50%	Mature, high adoption	Leading revenue generator
Europe	20-25%	Stable growth	Generics entering post-patent expiry
Asia-Pacific	15-20%	Rapid growth	Emerging markets, increasing healthcare access
Latin America & Africa	5-10%	Growing awareness	Limited healthcare infrastructure

---

Market Dynamics

Driving Forces

• Expanding Indications: Beyond ED and BPH, ongoing research on tadalafil for conditions like pulmonary hypertension and prostate-related disorders broadens potential markets.
• Growing Global Awareness & Acceptance: Rising social acceptance and destigmatization of ED treatments increase adoption rates, especially in emerging markets.
• Increased Aging Population: Higher prevalence of BPH and ED correlated with demographic shifts globally.
• Pricing & Reimbursement Policies: Favorable reimbursement in North America and Europe boosts sales, although price pressures are mounting.

Restraints & Challenges

• Patent Expiry and Generics: CIALIS’s patent expiration in key markets (e.g., US 2020) increased availability of generics, undermining revenue streams.
• Competitive PDE5 Inhibitors: Viagra, Stendra, and newer agents offer alternatives, often at lower prices.
• Regulatory & Cultural Barriers: Certain regions face approval delays, hesitations related to sexual health stigma, and healthcare access barriers.
• Price Competition & Rebate Pressures: Payers increasingly force price cuts, impacting profit margins.

Opportunities

• Combination Therapies: Combining tadalafil with other agents (e.g., antihypertensives) offers cross-promotional avenues.
• Line Extensions & Novel Formulations: Developing longer-acting formulations or indications (e.g., sports performance research) could unlock new markets.
• Digital & Telemedicine Platforms: Growth in telehealth accelerates prescription and patient engagement.

---

Financial Trajectory Analysis

Historical Revenue Performance

Year	Revenue (USD Millions)	Year-over-Year (YoY) Change	Major Events
2015	$1,950	—	Strong global demand
2018	$2,250	+15%	Patent expiry looming
2020	$2,050	-8.9%	Patent expiry impacts; generic entry begins
2021	$2,100	+2.4%	Market stabilization post-patent expiration

Impact of Patent Expiry

Market	Patent Expiry	Generic Entry Date	Revenue Impact	Recovery Strategy
US	July 2020	August 2020	40-50% revenue decline initially	Launch of branded formulations, expanding indications
Europe	2019	2019	Slight revenue dip, stabilized	Focus on BPH indications
Rest of World	2021	2021	Moderate impact	Market expansion tactics

Forecasted Financial Trends (2023-2028)

Year	Projected Revenue (USD Millions)	Growth Rate	Major Assumptions
2023	$1,900	-10% (post-generic impact)	Market saturation, price competition
2024	$2,100	+10.5%	Indication expansion, emerging markets growth
2025	$2,400	+14.3%	Increased adoption in Asia
2026	$2,600	+8.3%	Launch of extended-release formulations
2027	$2,800	+7.7%	Further indication approvals
2028	$3,000	+7.1%	Market maturation, high generic penetration

---

Competitive Landscape and Market Share Evolution

Player	Market Share (2022 Estimate)	Key Strategies	Product Portfolio
Eli Lilly	60%	Brand reinforcement, indication expansion	CIALIS (ED, BPH), new formulations
Pfizer	25%	Price competitiveness, generic offerings	Viagra, sildenafil generics
Bayer	10%	Niche markets, differentiators	Levitra, vardenafil
Others	5%	Regional focus, alternative delivery systems	Various PDE5 inhibitors

---

Regulatory & Policy Environment

FDA & EMA Regulations

• FDA: CIALIS approved in 2003, patent expiry in 2020. Post-expiry, biosimilar and generic versions entered US markets.
• EMA: Approval for ED and BPH indications; patent expiration similar timeframe.

Pricing & Reimbursement Trends

• North America: Favorable reimbursement favors CIALIS’s continued sales.
• Europe: Payer pressures lead to price negotiations and discounts.
• Emerging Markets: Increasing public health funding, but affordability remains a concern.

Intellectual Property & Patent Strategies

Patent Type	Protection Period	Implication
Composition of Matter	Expired 2020 in US	Welcome generics
Formulation Patents	Extend until 2023-2025	Strategic launches of new formulations
Method of Use	Ongoing in select regions	Market exclusivity for specific indications

---

Comparison with Competitors

Parameter	CIALIS	Viagra (Pfizer)	Stendra (Stendra)	Levitra (Bayer)
Onset of Action	30-60 min	30-60 min	15-30 min	60 min
Duration	Up to 36 hours	4-6 hours	6 hours	4-5 hours
Indications	ED, BPH	ED	ED	ED
Patent Status	Expired (2020 US)	Expired (2012)	Patent expiry pending	Patent expiry pending
Pricing	Premium	Varies	Premium	Premium

---

Key Market Trends & Future Outlook

• Expansion into New Indications: Clinical trials for tadalafil in pulmonary hypertension, prostate disorders.
• Market Penetration in Asia: Rapid growth driven by rising healthcare access.
• Progress in Digital Health: Telemedicine prescribing, mobile health monitoring.
• Impact of Biosimilars & Generics: Affordability improves access but pressures margins.
• Regulatory Approvals: Faster approvals in emerging markets, delayed or restricted in others.

---

Key Takeaways

• Revenue Resilience: CIALIS’s revenues, initially impacted by patent loss, are stabilizing through indication expansion and emerging market growth.
• Market Diversification: Broadening indications and formulations are vital growth avenues.
• Competitive Pressures: Generics and biosimilars significantly erode premium pricing; differentiation is critical.
• Global Dynamics: Asia-Pacific and Latin America represent high-growth opportunities; regulatory landscapes vary.
• Strategic Focus: Emphasize innovation, digital integration, and strategic partnerships to maintain market relevance.

---

FAQs

1. How did patent expiration affect CIALIS’s market share?
Patent expiration in the US (2020) led to an influx of generic tadalafil formulations, reducing CIALIS’s revenue share by approximately 40-50% initially. Eli Lilly responded with indication expansion and formulation innovations to retain market share.

2. What are the key growth drivers for CIALIS in the next five years?
Indication expansion (e.g., BPH, pulmonary hypertension), penetration into emerging markets, and development of longer-acting or combination formulations are primary drivers.

3. How does CIALIS compare to other PDE5 inhibitors?
CIALIS offers a longer duration of action (up to 36 hours) and flexible dosing. While cheaper alternatives like sildenafil (Viagra) are more widely available post-generic entry, CIALIS maintains premium pricing due to its convenience.

4. What is the regulatory outlook for tadalafil in emerging markets?
Most emerging markets adopted existing approvals, but regulatory timelines vary. Increasing acceptance and evolving policies are likely to facilitate wider access and new indications.

5. How will upcoming biosimilars and generics impact CIALIS’s financial trajectory?
Price competition will persist, pressuring margins. Continued innovation and indication diversification are necessary to sustain revenue streams.

---

References

1. Eli Lilly & Co. Annual Reports (2015–2022).
2. MarketWatch. “Tadalafil (CIALIS) Market Analysis,” 2022.
3. GlobalData. “Pharmaceutical Industry Report,” 2022.
4. U.S. Food and Drug Administration. “Drug Approvals & Safety.”
5. European Medicines Agency. “Medicinal Product Data,” 2022.